Bivalent Booster Effectiveness Against New SARS-CoV-2 Variants Bivalent Booster Effectiveness Against New SARS-CoV-2 Variants
This study confirms that a bivalent mRNA booster dose provides additional protection against symptomatic XBB/XBB.1.5 infection for at least 3 months after vaccination.Morbidity & Mortality Weekly Report
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news
More News: AIDS Vaccine | HIV AIDS | Infectious Diseases | International Medicine & Public Health | SARS | Study | Vaccines